| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 118 | 2021 | 5317 | 6.230 |
Why?
|
| Skin Neoplasms | 59 | 2021 | 4654 | 2.570 |
Why?
|
| Dacarbazine | 24 | 2017 | 485 | 1.790 |
Why?
|
| Programmed Cell Death 1 Receptor | 18 | 2021 | 1048 | 1.770 |
Why?
|
| Antibodies, Monoclonal, Humanized | 20 | 2020 | 3251 | 1.480 |
Why?
|
| CTLA-4 Antigen | 9 | 2021 | 657 | 1.420 |
Why?
|
| Antineoplastic Agents, Immunological | 8 | 2020 | 1249 | 1.360 |
Why?
|
| Antibodies, Monoclonal | 17 | 2017 | 4367 | 1.310 |
Why?
|
| Ipilimumab | 13 | 2020 | 710 | 1.260 |
Why?
|
| Interferon-alpha | 14 | 2018 | 889 | 1.160 |
Why?
|
| Antineoplastic Agents | 33 | 2017 | 14289 | 1.050 |
Why?
|
| Interleukin-2 | 9 | 2018 | 842 | 0.980 |
Why?
|
| Brain Neoplasms | 15 | 2019 | 4849 | 0.900 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 28 | 2020 | 15862 | 0.850 |
Why?
|
| Immunotherapy | 13 | 2019 | 3341 | 0.840 |
Why?
|
| Recombinant Proteins | 13 | 2018 | 2927 | 0.830 |
Why?
|
| Antineoplastic Agents, Alkylating | 7 | 2016 | 588 | 0.690 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2020 | 598 | 0.670 |
Why?
|
| Neoplasm Metastasis | 21 | 2019 | 5112 | 0.660 |
Why?
|
| Clinical Trials as Topic | 7 | 2020 | 3719 | 0.640 |
Why?
|
| Neoplasm Proteins | 4 | 2018 | 3230 | 0.620 |
Why?
|
| Neoplasm Staging | 29 | 2020 | 13658 | 0.610 |
Why?
|
| Melanocytes | 4 | 2021 | 219 | 0.600 |
Why?
|
| Middle Aged | 90 | 2021 | 86204 | 0.550 |
Why?
|
| Biomarkers, Tumor | 14 | 2021 | 10331 | 0.550 |
Why?
|
| Immunohistochemistry | 10 | 2021 | 7548 | 0.540 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2020 | 2232 | 0.540 |
Why?
|
| Male | 96 | 2021 | 123000 | 0.520 |
Why?
|
| Antigens, Neoplasm | 4 | 2018 | 1506 | 0.510 |
Why?
|
| Female | 101 | 2021 | 141928 | 0.500 |
Why?
|
| Aged | 77 | 2021 | 70117 | 0.500 |
Why?
|
| Paraneoplastic Syndromes | 2 | 2005 | 82 | 0.480 |
Why?
|
| Humans | 135 | 2021 | 261506 | 0.480 |
Why?
|
| Adult | 70 | 2021 | 77950 | 0.450 |
Why?
|
| Polyethylene Glycols | 6 | 2018 | 615 | 0.450 |
Why?
|
| Decision Making | 1 | 2020 | 1287 | 0.430 |
Why?
|
| Thalidomide | 6 | 2010 | 569 | 0.430 |
Why?
|
| Survival Rate | 23 | 2021 | 12221 | 0.400 |
Why?
|
| Aged, 80 and over | 37 | 2021 | 29902 | 0.400 |
Why?
|
| Treatment Outcome | 36 | 2019 | 32848 | 0.360 |
Why?
|
| Cancer Vaccines | 6 | 2013 | 697 | 0.350 |
Why?
|
| Adjuvants, Immunologic | 4 | 2018 | 657 | 0.350 |
Why?
|
| Proto-Oncogene Proteins B-raf | 7 | 2018 | 1283 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2054 | 0.350 |
Why?
|
| Drug Eruptions | 5 | 2018 | 256 | 0.340 |
Why?
|
| Gangliosides | 3 | 2004 | 95 | 0.340 |
Why?
|
| Disease-Free Survival | 16 | 2020 | 10001 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2018 | 4938 | 0.330 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2018 | 992 | 0.320 |
Why?
|
| Lymphopenia | 2 | 2010 | 199 | 0.320 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 550 | 0.310 |
Why?
|
| Telomerase | 2 | 2021 | 525 | 0.300 |
Why?
|
| Carcinoma, Renal Cell | 8 | 2018 | 2326 | 0.300 |
Why?
|
| Positron-Emission Tomography | 3 | 2012 | 2173 | 0.290 |
Why?
|
| Conjunctival Neoplasms | 2 | 2018 | 120 | 0.280 |
Why?
|
| Skin Diseases | 2 | 2014 | 349 | 0.280 |
Why?
|
| Paclitaxel | 5 | 2018 | 1996 | 0.280 |
Why?
|
| Osteoarthropathy, Secondary Hypertrophic | 1 | 2005 | 2 | 0.280 |
Why?
|
| Oximes | 3 | 2018 | 175 | 0.280 |
Why?
|
| Combined Modality Therapy | 12 | 2018 | 8865 | 0.270 |
Why?
|
| Vaccines, Conjugate | 2 | 2004 | 76 | 0.250 |
Why?
|
| Young Adult | 19 | 2021 | 21445 | 0.240 |
Why?
|
| Uveal Neoplasms | 4 | 2010 | 176 | 0.240 |
Why?
|
| Hemocyanins | 1 | 2003 | 50 | 0.240 |
Why?
|
| Eye Neoplasms | 1 | 2006 | 247 | 0.230 |
Why?
|
| Remission Induction | 10 | 2015 | 3569 | 0.230 |
Why?
|
| Immunologic Factors | 2 | 2010 | 649 | 0.230 |
Why?
|
| Drug Administration Schedule | 13 | 2019 | 3472 | 0.230 |
Why?
|
| Melanosis | 1 | 2003 | 16 | 0.230 |
Why?
|
| Neutropenia | 4 | 2014 | 968 | 0.230 |
Why?
|
| Nausea | 5 | 2018 | 525 | 0.230 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 848 | 0.220 |
Why?
|
| Neoplasms | 9 | 2018 | 15193 | 0.220 |
Why?
|
| Imidazoles | 3 | 2018 | 999 | 0.200 |
Why?
|
| Lymphocyte Count | 4 | 2017 | 486 | 0.200 |
Why?
|
| Kidney Neoplasms | 6 | 2018 | 3022 | 0.200 |
Why?
|
| Nails | 1 | 2021 | 36 | 0.200 |
Why?
|
| Vomiting | 4 | 2012 | 354 | 0.200 |
Why?
|
| Disease Progression | 9 | 2020 | 6682 | 0.190 |
Why?
|
| Anus Neoplasms | 1 | 2005 | 411 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 5178 | 0.190 |
Why?
|
| Mouth Neoplasms | 1 | 2006 | 713 | 0.190 |
Why?
|
| Thymidine | 2 | 1997 | 155 | 0.190 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2021 | 907 | 0.190 |
Why?
|
| Frontal Lobe | 1 | 2001 | 187 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2018 | 3890 | 0.190 |
Why?
|
| Maximum Tolerated Dose | 5 | 2018 | 1290 | 0.190 |
Why?
|
| Survival Analysis | 12 | 2021 | 9180 | 0.190 |
Why?
|
| B7-H1 Antigen | 5 | 2020 | 1022 | 0.180 |
Why?
|
| Nevus, Blue | 1 | 2020 | 40 | 0.180 |
Why?
|
| Fatigue | 6 | 2018 | 1239 | 0.180 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 276 | 0.180 |
Why?
|
| Indoles | 3 | 2014 | 1009 | 0.180 |
Why?
|
| Cisplatin | 9 | 2014 | 2432 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2018 | 7551 | 0.180 |
Why?
|
| Prognosis | 14 | 2021 | 21713 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2018 | 4757 | 0.170 |
Why?
|
| Nanotechnology | 1 | 2019 | 137 | 0.170 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2020 | 216 | 0.170 |
Why?
|
| Pyrimidinones | 2 | 2018 | 314 | 0.170 |
Why?
|
| Enterocolitis | 1 | 2018 | 43 | 0.160 |
Why?
|
| Interleukin-9 | 1 | 2018 | 37 | 0.160 |
Why?
|
| Monophenol Monooxygenase | 2 | 2012 | 59 | 0.160 |
Why?
|
| Infliximab | 1 | 2018 | 130 | 0.160 |
Why?
|
| Pyridones | 2 | 2018 | 348 | 0.160 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 108 | 0.160 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 14889 | 0.160 |
Why?
|
| Pyrrolidines | 1 | 2018 | 113 | 0.150 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2017 | 299 | 0.150 |
Why?
|
| Adolescent | 16 | 2021 | 31252 | 0.150 |
Why?
|
| Facial Neoplasms | 1 | 2018 | 84 | 0.150 |
Why?
|
| Exanthema | 2 | 2017 | 211 | 0.150 |
Why?
|
| Neoplasms, Second Primary | 3 | 2018 | 1350 | 0.150 |
Why?
|
| Carboplatin | 2 | 2018 | 823 | 0.150 |
Why?
|
| Electric Stimulation Therapy | 1 | 2017 | 116 | 0.140 |
Why?
|
| Patient Positioning | 1 | 2018 | 195 | 0.140 |
Why?
|
| Indazoles | 1 | 2018 | 297 | 0.140 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 134 | 0.140 |
Why?
|
| Health Status Indicators | 1 | 2017 | 224 | 0.140 |
Why?
|
| Liver Neoplasms | 4 | 2018 | 4557 | 0.130 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2015 | 31 | 0.130 |
Why?
|
| Cohort Studies | 9 | 2020 | 9244 | 0.130 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 361 | 0.130 |
Why?
|
| Orbital Neoplasms | 1 | 2017 | 224 | 0.130 |
Why?
|
| Retrospective Studies | 18 | 2021 | 37905 | 0.130 |
Why?
|
| Sialic Acids | 1 | 1994 | 29 | 0.130 |
Why?
|
| Sulfonamides | 2 | 2014 | 1823 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 544 | 0.130 |
Why?
|
| Clonal Evolution | 1 | 2017 | 253 | 0.130 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 315 | 0.130 |
Why?
|
| Biopsy | 6 | 2021 | 3443 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2016 | 242 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2016 | 582 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2018 | 1763 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 673 | 0.120 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1994 | 87 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 487 | 0.120 |
Why?
|
| Foot Dermatoses | 1 | 2014 | 23 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2001 | 1248 | 0.120 |
Why?
|
| Aorta | 1 | 2018 | 692 | 0.120 |
Why?
|
| Sweet Syndrome | 1 | 2014 | 36 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2018 | 1586 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2014 | 479 | 0.120 |
Why?
|
| Salvage Therapy | 1 | 2002 | 2054 | 0.120 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 4988 | 0.120 |
Why?
|
| Lymphatic Metastasis | 7 | 2020 | 4844 | 0.120 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 4744 | 0.120 |
Why?
|
| Biphenyl Compounds | 1 | 1995 | 194 | 0.120 |
Why?
|
| Triazoles | 1 | 2018 | 617 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2013 | 23 | 0.110 |
Why?
|
| Pyridines | 2 | 2018 | 1244 | 0.110 |
Why?
|
| Leuprolide | 1 | 2013 | 65 | 0.110 |
Why?
|
| Vinblastine | 4 | 2011 | 453 | 0.110 |
Why?
|
| Esophageal Neoplasms | 2 | 2003 | 3168 | 0.110 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2017 | 591 | 0.110 |
Why?
|
| Leukocyte Count | 1 | 2014 | 684 | 0.110 |
Why?
|
| Carmustine | 3 | 2003 | 214 | 0.110 |
Why?
|
| Lung Neoplasms | 4 | 2018 | 11538 | 0.110 |
Why?
|
| Melanins | 1 | 2012 | 50 | 0.110 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2012 | 81 | 0.110 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2012 | 47 | 0.110 |
Why?
|
| Mutation | 10 | 2020 | 15179 | 0.110 |
Why?
|
| Vaccines, Subunit | 1 | 2013 | 124 | 0.110 |
Why?
|
| Time Factors | 11 | 2021 | 12926 | 0.110 |
Why?
|
| Cancer Pain | 1 | 2017 | 312 | 0.110 |
Why?
|
| Lymphocyte Subsets | 1 | 2012 | 137 | 0.110 |
Why?
|
| Serotonin Antagonists | 1 | 2012 | 41 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 1823 | 0.100 |
Why?
|
| Quinuclidines | 1 | 2012 | 48 | 0.100 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 2283 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2017 | 4804 | 0.100 |
Why?
|
| Prospective Studies | 7 | 2018 | 12873 | 0.100 |
Why?
|
| Doxorubicin | 1 | 1999 | 3005 | 0.100 |
Why?
|
| alpha-Synuclein | 1 | 2012 | 118 | 0.100 |
Why?
|
| Isoquinolines | 1 | 2012 | 116 | 0.100 |
Why?
|
| Intracranial Hemorrhages | 1 | 2012 | 121 | 0.100 |
Why?
|
| Choroid Neoplasms | 1 | 2011 | 41 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 3 | 2018 | 4975 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 3 | 2012 | 3976 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2020 | 10035 | 0.100 |
Why?
|
| Hepatic Insufficiency | 1 | 2010 | 34 | 0.100 |
Why?
|
| Biomarkers | 3 | 2017 | 5047 | 0.100 |
Why?
|
| Antiemetics | 1 | 2012 | 125 | 0.090 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 2864 | 0.090 |
Why?
|
| Fluorouracil | 1 | 1995 | 1944 | 0.090 |
Why?
|
| Anxiety | 1 | 2017 | 1179 | 0.090 |
Why?
|
| Tumor Escape | 1 | 2012 | 251 | 0.090 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 419 | 0.090 |
Why?
|
| Interferon-gamma | 3 | 1996 | 1144 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 980 | 0.090 |
Why?
|
| Pelvis | 1 | 2011 | 362 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 2315 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 7702 | 0.080 |
Why?
|
| Genomics | 1 | 2020 | 2738 | 0.080 |
Why?
|
| Interferon-beta | 2 | 1996 | 102 | 0.080 |
Why?
|
| Extremities | 2 | 1998 | 303 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2015 | 2291 | 0.080 |
Why?
|
| Animals | 10 | 2021 | 59536 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 1033 | 0.080 |
Why?
|
| Azacitidine | 1 | 2014 | 1149 | 0.080 |
Why?
|
| Interferons | 2 | 2008 | 291 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2015 | 829 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 335 | 0.080 |
Why?
|
| Depression | 1 | 2017 | 1715 | 0.080 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2019 | 160 | 0.080 |
Why?
|
| Immunotherapy, Active | 1 | 2007 | 46 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2012 | 1016 | 0.070 |
Why?
|
| Saponins | 2 | 2003 | 34 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2021 | 2218 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2012 | 787 | 0.070 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 4892 | 0.070 |
Why?
|
| Lymphokines | 2 | 1988 | 272 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2018 | 259 | 0.070 |
Why?
|
| Vincristine | 1 | 2010 | 1511 | 0.070 |
Why?
|
| Quinazolines | 1 | 2011 | 923 | 0.070 |
Why?
|
| Peritoneum | 1 | 2006 | 150 | 0.070 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 1997 | 169 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2019 | 6207 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2010 | 852 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2018 | 280 | 0.070 |
Why?
|
| Immunoglobulin M | 2 | 2004 | 347 | 0.070 |
Why?
|
| Immunoglobulin G | 3 | 2004 | 1021 | 0.070 |
Why?
|
| Infusions, Intravenous | 4 | 2011 | 1382 | 0.070 |
Why?
|
| Contrast Media | 1 | 2012 | 1472 | 0.070 |
Why?
|
| Administration, Oral | 3 | 2018 | 1544 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2021 | 6869 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2009 | 479 | 0.060 |
Why?
|
| Risk Factors | 6 | 2021 | 17523 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2013 | 840 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 7789 | 0.060 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2004 | 64 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2004 | 101 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2014 | 2669 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 846 | 0.060 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2003 | 84 | 0.060 |
Why?
|
| Drainage | 2 | 2001 | 416 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 1489 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2008 | 441 | 0.060 |
Why?
|
| T-Lymphocytes | 4 | 2017 | 3869 | 0.060 |
Why?
|
| Genital Diseases, Male | 1 | 2003 | 27 | 0.060 |
Why?
|
| Anus Diseases | 1 | 2003 | 29 | 0.060 |
Why?
|
| United States | 2 | 2017 | 15433 | 0.060 |
Why?
|
| Potassium Channels | 1 | 2004 | 162 | 0.060 |
Why?
|
| Lactones | 1 | 2003 | 94 | 0.060 |
Why?
|
| Child, Preschool | 5 | 2021 | 16273 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2006 | 1391 | 0.060 |
Why?
|
| Antibody Specificity | 1 | 2003 | 334 | 0.060 |
Why?
|
| Nurse's Role | 1 | 2003 | 42 | 0.060 |
Why?
|
| Nipples | 1 | 2003 | 132 | 0.050 |
Why?
|
| Life Tables | 1 | 2002 | 120 | 0.050 |
Why?
|
| Penis | 1 | 2003 | 123 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2003 | 383 | 0.050 |
Why?
|
| Acetaminophen | 1 | 2003 | 116 | 0.050 |
Why?
|
| Child | 6 | 2021 | 29154 | 0.050 |
Why?
|
| Radiotherapy | 1 | 2009 | 1824 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2018 | 756 | 0.050 |
Why?
|
| DNA Copy Number Variations | 2 | 2020 | 1516 | 0.050 |
Why?
|
| HLA-A2 Antigen | 1 | 2002 | 159 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2017 | 5319 | 0.050 |
Why?
|
| Models, Biological | 1 | 2010 | 3254 | 0.050 |
Why?
|
| Drug Costs | 1 | 2002 | 144 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 4971 | 0.050 |
Why?
|
| Diarrhea | 2 | 2018 | 686 | 0.050 |
Why?
|
| Neutrophil Activation | 1 | 2020 | 34 | 0.050 |
Why?
|
| Half-Life | 2 | 2010 | 259 | 0.050 |
Why?
|
| Vaccination | 2 | 2003 | 1123 | 0.050 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 300 | 0.040 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 14551 | 0.040 |
Why?
|
| Lymph Node Excision | 2 | 2003 | 1959 | 0.040 |
Why?
|
| Foot | 1 | 2020 | 104 | 0.040 |
Why?
|
| ErbB Receptors | 2 | 2011 | 2295 | 0.040 |
Why?
|
| Mice | 6 | 2021 | 34495 | 0.040 |
Why?
|
| Taxoids | 2 | 2016 | 967 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2013 | 1146 | 0.040 |
Why?
|
| Hand | 1 | 2020 | 170 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2002 | 749 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2003 | 1681 | 0.040 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2001 | 156 | 0.040 |
Why?
|
| Glioma | 1 | 2010 | 1963 | 0.040 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1999 | 171 | 0.040 |
Why?
|
| Incidence | 2 | 2019 | 5673 | 0.040 |
Why?
|
| Lymphatic Vessels | 1 | 2019 | 143 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 2006 | 1202 | 0.040 |
Why?
|
| Optical Imaging | 1 | 2019 | 157 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 945 | 0.040 |
Why?
|
| Preliminary Data | 1 | 2017 | 12 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 2001 | 374 | 0.040 |
Why?
|
| Biological Availability | 1 | 2018 | 214 | 0.040 |
Why?
|
| New Zealand | 1 | 2017 | 60 | 0.040 |
Why?
|
| Skin | 1 | 2003 | 1259 | 0.040 |
Why?
|
| Hepatic Artery | 1 | 1999 | 240 | 0.040 |
Why?
|
| Exocytosis | 1 | 1988 | 111 | 0.040 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2019 | 221 | 0.040 |
Why?
|
| Lymphocyte Activation | 3 | 2017 | 1688 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 2018 | 85 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 430 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2020 | 731 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1988 | 212 | 0.040 |
Why?
|
| Australia | 1 | 2017 | 225 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2018 | 98 | 0.040 |
Why?
|
| Ribosomal Protein S6 | 1 | 2016 | 46 | 0.040 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2017 | 149 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 1491 | 0.040 |
Why?
|
| Glutaral | 1 | 1976 | 15 | 0.040 |
Why?
|
| Metagenome | 1 | 2017 | 176 | 0.040 |
Why?
|
| Saliva | 1 | 2017 | 231 | 0.040 |
Why?
|
| Aldehydes | 1 | 1976 | 44 | 0.040 |
Why?
|
| Standard of Care | 1 | 2018 | 243 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2018 | 278 | 0.030 |
Why?
|
| Dogs | 1 | 2018 | 1155 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 503 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 2016 | 170 | 0.030 |
Why?
|
| Eyelid Neoplasms | 1 | 2018 | 191 | 0.030 |
Why?
|
| Clone Cells | 1 | 2017 | 555 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 1996 | 573 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 3981 | 0.030 |
Why?
|
| Drug Design | 1 | 1997 | 375 | 0.030 |
Why?
|
| Artifacts | 1 | 2018 | 532 | 0.030 |
Why?
|
| Patient Selection | 1 | 2003 | 2055 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 1994 | 34 | 0.030 |
Why?
|
| Tumor Burden | 2 | 2012 | 1987 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2015 | 257 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1986 | 388 | 0.030 |
Why?
|
| Uridine | 1 | 1995 | 59 | 0.030 |
Why?
|
| Infant | 2 | 2020 | 13310 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 672 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1997 | 1313 | 0.030 |
Why?
|
| Pruritus | 1 | 2014 | 87 | 0.030 |
Why?
|
| Pulmonary Embolism | 2 | 2008 | 329 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1997 | 750 | 0.030 |
Why?
|
| Texas | 2 | 2018 | 6311 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2017 | 829 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2016 | 639 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 1053 | 0.030 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2013 | 88 | 0.030 |
Why?
|
| Actins | 1 | 1976 | 608 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2013 | 64 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2020 | 1415 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 672 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 884 | 0.030 |
Why?
|
| Interleukin-7 | 1 | 2013 | 95 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 6942 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2015 | 665 | 0.030 |
Why?
|
| Dopaminergic Neurons | 1 | 2012 | 51 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2015 | 604 | 0.030 |
Why?
|
| Monocytes | 1 | 1986 | 788 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 336 | 0.030 |
Why?
|
| Palliative Care | 2 | 2001 | 2037 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2000 | 1390 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2292 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 287 | 0.030 |
Why?
|
| Pain Management | 1 | 2017 | 668 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 528 | 0.020 |
Why?
|
| BCG Vaccine | 2 | 2004 | 399 | 0.020 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2010 | 15 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2012 | 699 | 0.020 |
Why?
|
| Benzenesulfonates | 1 | 2012 | 195 | 0.020 |
Why?
|
| Dopamine | 1 | 2012 | 312 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2017 | 1555 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2010 | 65 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2012 | 15694 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 476 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 231 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2012 | 5637 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2012 | 575 | 0.020 |
Why?
|
| Niacinamide | 1 | 2012 | 421 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2014 | 1090 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2010 | 334 | 0.020 |
Why?
|
| Ascites | 1 | 2010 | 198 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 1439 | 0.020 |
Why?
|
| Survivors | 1 | 2015 | 1031 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 700 | 0.020 |
Why?
|
| Safety | 1 | 2011 | 465 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3821 | 0.020 |
Why?
|
| Telomere | 1 | 2012 | 505 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 2265 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 6086 | 0.020 |
Why?
|
| Transcriptome | 1 | 2017 | 1859 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 170 | 0.020 |
Why?
|
| Liposomes | 1 | 2010 | 684 | 0.020 |
Why?
|
| Age Factors | 2 | 2008 | 5377 | 0.020 |
Why?
|
| Receptors, Concanavalin A | 1 | 1978 | 2 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 2009 | 177 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 580 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 660 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 1914 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2008 | 257 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 324 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2009 | 193 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2020 | 7226 | 0.020 |
Why?
|
| Lipid A | 1 | 2007 | 30 | 0.020 |
Why?
|
| DNA Mismatch Repair | 1 | 2009 | 268 | 0.020 |
Why?
|
| Sirolimus | 1 | 2012 | 814 | 0.020 |
Why?
|
| Thiotepa | 1 | 1997 | 118 | 0.020 |
Why?
|
| Perfusion | 1 | 1998 | 293 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2016 | 11965 | 0.020 |
Why?
|
| Mental Processes | 1 | 1996 | 53 | 0.020 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 1996 | 55 | 0.020 |
Why?
|
| Edema | 1 | 1998 | 267 | 0.020 |
Why?
|
| Cytokines | 1 | 2015 | 2809 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 3045 | 0.020 |
Why?
|
| Leukopenia | 1 | 1996 | 151 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2006 | 161 | 0.020 |
Why?
|
| Parkinson Disease | 1 | 2012 | 708 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 2139 | 0.020 |
Why?
|
| Proteinuria | 1 | 1996 | 155 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2007 | 621 | 0.020 |
Why?
|
| Headache | 1 | 1996 | 163 | 0.020 |
Why?
|
| Anorexia | 1 | 1996 | 143 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 1996 | 161 | 0.020 |
Why?
|
| Melphalan | 1 | 1998 | 834 | 0.020 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2004 | 7 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 2007 | 492 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6009 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 3890 | 0.020 |
Why?
|
| Injections, Intradermal | 1 | 2004 | 58 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2004 | 84 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2004 | 182 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2004 | 110 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 3570 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 5159 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2014 | 2819 | 0.010 |
Why?
|
| Logistic Models | 1 | 2011 | 3441 | 0.010 |
Why?
|
| Glutathione Reductase | 1 | 2003 | 17 | 0.010 |
Why?
|
| Brain | 1 | 2017 | 4113 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 2003 | 80 | 0.010 |
Why?
|
| Fever | 1 | 1996 | 497 | 0.010 |
Why?
|
| Tamoxifen | 1 | 1997 | 876 | 0.010 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 384 | 0.010 |
Why?
|
| Freund's Adjuvant | 1 | 2002 | 43 | 0.010 |
Why?
|
| Immunization | 1 | 2004 | 397 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2330 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 2003 | 143 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2003 | 126 | 0.010 |
Why?
|
| Cetuximab | 1 | 2003 | 472 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 1993 | 231 | 0.010 |
Why?
|
| Sclerotherapy | 1 | 2001 | 48 | 0.010 |
Why?
|
| Pleurodesis | 1 | 2001 | 71 | 0.010 |
Why?
|
| Weight Loss | 1 | 1995 | 627 | 0.010 |
Why?
|
| Glutathione | 1 | 2003 | 368 | 0.010 |
Why?
|
| Pain | 1 | 2009 | 1658 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2002 | 408 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1995 | 779 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 1978 | 1270 | 0.010 |
Why?
|
| Chest Tubes | 1 | 2001 | 101 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2003 | 709 | 0.010 |
Why?
|
| Thoracic Neoplasms | 1 | 1993 | 337 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1996 | 732 | 0.010 |
Why?
|
| Recurrence | 1 | 1998 | 4758 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 2012 | 2278 | 0.010 |
Why?
|
| Lymphocyte Cooperation | 1 | 1988 | 11 | 0.010 |
Why?
|
| Mice, Inbred AKR | 1 | 1988 | 51 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1988 | 76 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1995 | 4298 | 0.010 |
Why?
|
| Equipment Design | 1 | 2001 | 1204 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1997 | 104 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1986 | 52 | 0.010 |
Why?
|
| Calcimycin | 1 | 1986 | 48 | 0.010 |
Why?
|
| Nucleotides, Cyclic | 1 | 1986 | 10 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 1988 | 284 | 0.010 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 1986 | 34 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1986 | 71 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1986 | 67 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 3578 | 0.010 |
Why?
|
| Tropomyosin | 1 | 1976 | 38 | 0.010 |
Why?
|
| Colon | 1 | 2000 | 670 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2002 | 1271 | 0.010 |
Why?
|
| Enterotoxins | 1 | 1986 | 112 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 4638 | 0.010 |
Why?
|
| Troponin | 1 | 1976 | 92 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1976 | 293 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1976 | 209 | 0.010 |
Why?
|
| Magnesium | 1 | 1976 | 160 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1986 | 295 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 5061 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 1997 | 368 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 1976 | 435 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 1995 | 2576 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1976 | 1764 | 0.010 |
Why?
|
| Binding Sites | 1 | 1976 | 2171 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 1997 | 904 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1997 | 5395 | 0.010 |
Why?
|
| Protein Binding | 1 | 1976 | 3438 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1978 | 60 | 0.010 |
Why?
|
| Diffusion | 1 | 1978 | 88 | 0.000 |
Why?
|
| Xenopus laevis | 1 | 1978 | 270 | 0.000 |
Why?
|
| Embryo, Nonmammalian | 1 | 1978 | 234 | 0.000 |
Why?
|
| Electric Stimulation | 1 | 1978 | 426 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1978 | 850 | 0.000 |
Why?
|